20:32 , Jun 2, 2017 |  BC Week In Review  |  Clinical News

Medicines Co., Alnylam to begin Phase III program of inclisiran

Next half, The Medicines Co. (NASDAQ:MDCO) and Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) plan to begin placebo-controlled Phase III trials to evaluate 300 mg subcutaneous inclisiran on day 1, 90 and every 6 months thereafter for a...
02:11 , Feb 23, 2017 |  BC Week In Review  |  Clinical News

Inclisiran: extension study started

The Medicines Co. began the open-label ORION-3 extension study to compare subcutaneous inclisiran vs. Repatha evolocumab in patients who have completed the double-blind, placebo-controlled, international Phase II ORION-1 trial. Patients who received inclisiran in ORION-1...
21:45 , Feb 1, 2017 |  BC Week In Review  |  Clinical News

Inclisiran: Ph II ORION-2 started

The Medicines Co. began the open-label, Dutch Phase II ORION-2 trial to evaluate 300 mg subcutaneous inclisiran in about 10 patients. Patients whose mean serum PCSK9 levels are not suppressed by >70% at days 60...
18:29 , Nov 18, 2016 |  BC Week In Review  |  Clinical News

Inclisiran: Additional Ph II ORION-1 data

Additional data from the double-blind, international Phase II ORION-1 trial in 497 patients with atherosclerotic cardiovascular disease or atherosclerotic cardiovascular disease-risk equivalents and elevated LDL-C despite receiving maximum tolerated doses of LDL-C-lowering therapies showed that...
23:21 , Nov 3, 2016 |  BC Week In Review  |  Clinical News

PCSK9si: Interim Ph II data

Interim data from the double-blind, placebo-controlled, international Phase II ORION-1 trial in 501 patients with atherosclerotic cardiovascular disease or atherosclerotic cardiovascular disease-risk equivalents and elevated LDL-C despite receiving maximum tolerated doses of LDL-C-lowering therapies showed...
01:25 , May 10, 2016 |  BC Extra  |  Company News

Medicines Co. selling some CV assets to Chiesi

The Medicines Co. (NASDAQ:MDCO) is selling its non-core cardiovascular assets to Chiesi Farmaceutici S.p.A. (Parma, Italy). The deal includes Cleviprex clevidipine, Kengreal cangrelor and the company's rights to ready to use argatroban. It does not...
08:00 , Feb 15, 2016 |  BC Week In Review  |  Clinical News

ALN-PCSsc: Phase II started

The Medicines Co. began the double-blind, placebo-controlled, international Phase II ORION-1 trial to evaluate single or multiple, quarterly or biannual subcutaneous ALN-PCSsc in about 480 patients with atherosclerotic cardiovascular disease (ASCVD) or risk equivalent-ASCVD and...
01:51 , Jan 21, 2016 |  BC Extra  |  Company News

Medicines Co. gains on takeout rumors

The Medicines Co. (NASDAQ:MDCO) gained $4.55 (14%) to $36.06 on Wednesday, giving it a market cap of $2.5 billion, after media reports said the company is exploring a sale. Spokesperson Robert Laverty declined to comment...
08:00 , Nov 16, 2015 |  BC Week In Review  |  Clinical News

ALN-PCSsc: Updated Phase I data

The partners reported updated data from a single-blind, placebo-controlled, U.K. Phase I trial in 69 healthy subjects on or off statins with elevated baseline LDL-C levels of >100 mg/dL evaluating single and multiple doses of...
07:00 , Sep 7, 2015 |  BC Week In Review  |  Clinical News

ALN-PCSsc: Phase I data

A single-blind, placebo-controlled, U.K. Phase I trial in 69 healthy subjects on or off statins with elevated baseline LDL-C levels of >100 mg/dL showed that single and multiple doses of subcutaneous ALN-PCSsc were generally well...